-+ 0.00%
-+ 0.00%
-+ 0.00%

Scribe Therapeutics To Present Data In American Heart Association’s Scientific Sessions On Its Three Clinical Programs

Benzinga·11/04/2026 13:08:15

Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced its participation in the American Heart Association’s Scientific Sessions taking place in Chicago, IL, from November 6-9, 2026.